Advanced Medical Isotope Corp. to Present at 11th Annual Life Science Innovation Northwest Conference in Seattle

CEO Jim Katzaroff to Address Attendees at 11:20 am PT on March 2

        Print
| Source: Advanced Medical Isotope Corporation

KENNEWICK, Wash., Feb. 24, 2011 (GLOBE NEWSWIRE) -- James Katzaroff, Chairman and Chief Executive Officer of Advanced Medical Isotope Corporation (OTCBB:ADMD), will present at the 11th Annual Life Science Innovation Northwest Conference to be held at the Washington State Convention Center in Seattle on March 2-3. Mr. Katzaroff's presentation will take place in the Medical Technology track at 11:20 am PT, and will provide an overview of the Company and its ongoing programs to produce Molybdenum-99 (Mo-99), as well as other initiatives that the company is actively pursuing.

Mo-99 is the most commonly used medical isotope in the world and is facing a critical shortage due to a small number of processing facilities and aging reactors. In response to this ongoing crisis, AMIC is developing methods to produce Mo-99 and other radioisotopes without needing a nuclear reactor, instead using a device the approximate size of a commercial cyclotron for production. AMIC has development programs in place to produce Mo-99 with high yields at a significant reduction in cost compared to isotopes made from nuclear plant methods.

The Washington Biotechnology & Biomedical Association (WBBA), in partnership with Burrill & Company, is hosting the conference, which brings together more than 70 presenting organizations and 700 attendees from public and private companies, research institutions, investors, scientists, and entrepreneurs focused on business development and partnering opportunities in life sciences. The conference highlights the unique innovative environment of the Pacific Northwest's life science sector and features medical technology, diagnostics and therapeutic innovations, as well as cutting-edge scientific and educational developments in global health. CLICK HERE for a fact sheet on the conference. 

About Advanced Medical Isotope Corporation

Advanced Medical Isotope Corporation (OTCBB:ADMD) is a company engaged in the production and distribution of medical isotopes for advanced diagnostic and non-surgical therapeutic application. AMIC's goal is to empower physicians, medical researchers, and ultimately patients by providing them with essential medical isotopes that, until recently, have not been feasible or economical, in an effort to detect and cure human disease. For more information, please visit our website, www.isotopeworld.com.

The Advanced Medical Isotope Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=5139

About LSINW 2011

Life Science Innovation Northwest 2011 is presented by The Washington Biotechnology & Biomedical Association (WBBA) and Burrill & Company. For more information on the LSINW 2011 conference, please visit www.washbio.org.

About WBBA

The Washington Biotechnology & Biomedical Association (WBBA) is an independent, non-profit 501(c)(6) trade association serving the life sciences industry in the state of Washington. Our members include organizations engaged in, or supportive of, research, development and commercialization of life science technologies. Our mission is to translate innovation to realization: from breakthrough discoveries to better health solutions. Learn more about the WBBA at www.washbio.org.

Safe Harbor Statement

The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, government agency rules and changes, and various other factors beyond the Company's control.

Advanced Medical Isotope Corporation
James C. Katzaroff
Kennewick, Washington
(509) 736-4000

The Investor Relations Group
11 Stone St. 3rd Floor
New York, NY
212-825-3210
IR: Adam Holdsworth/James Carbonara
or
PR: Laura Colontrelle/Janet Vasquez